Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.13 USD | +1.34% | +5.09% | +54.92% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
Financials (USD)
Sales 2024 * | 553M | Sales 2025 * | 592M | Capitalization | 2.49B |
---|---|---|---|---|---|
Net income 2024 * | -175M | Net income 2025 * | -188M | EV / Sales 2024 * | 4.34 x |
Net cash position 2024 * | 90.5M | Net Debt 2025 * | 59M | EV / Sales 2025 * | 4.3 x |
P/E ratio 2024 * |
-14.4
x | P/E ratio 2025 * |
-13.5
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | +1.34% | ||
1 week | +5.09% | ||
Current month | +5.09% | ||
1 month | +56.50% | ||
3 months | +41.90% | ||
6 months | +81.13% | ||
Current year | +54.92% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 63 | 11-08-04 |
David Hung
BRD | Director/Board Member | 67 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 17 M€ | +8.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 23.13 | +1.36% | 762,100 |
24-06-04 | 22.82 | -4.48% | 1,150,047 |
24-06-03 | 23.89 | +8.54% | 1,507,683 |
24-05-31 | 22.01 | -1.17% | 1,483,720 |
24-05-30 | 22.27 | +1.18% | 1,206,916 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.92% | 2.49B | |
+75.69% | 12.57B | |
+6.32% | 6.62B | |
+14.03% | 5.45B | |
-16.76% | 4.88B | |
+20.13% | 4.29B | |
-20.15% | 4.06B | |
-22.44% | 2.93B | |
+1.98% | 2.06B | |
+12.16% | 2.01B |
- Stock Market
- Equities
- NVCR Stock